ClinicalTrials.gg
Active, not recruitingNCT03876262Updated Dec 23, 2025

Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis

A Phase 3 interventional study of Moxidectin and Ivermectin in Onchocerciasis, sponsored by Medicines Development for Global Health. Active, not recruiting at 1 site in Democratic Republic of the Congo. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Medicines Development for Global Health · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
323
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The primary purpose of this phase 3b study is to determine the safety and efficacy of moxidectin administration twice a year, compared to once a year, in maintaining undetectable levels in skin of O. volvulus microfilaria in skin, the parasite that causes river blindness.

Secondary purposes are to determine the effectiveness of moxidectin compared to ivermectin once or twice a year in maintaining undetectable levels, or reducing levels, of skin microfilaria.

02

Conditions studied

  • Onchocerciasis

Browse trials for

03

In context

Onchocerciasis

35 studies on the registry are indexed under Onchocerciasis; 7 are open to participants now.

This study's enrollment of 323 is above the median of 216 across 26 interventional studies indexed under Onchocerciasis.

Browse Onchocerciasis studies →

Lead sponsor

Medicines Development for Global Health is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written , or assent with parental or guardian written consent.
  • Mean ≥ 10 O. volvulus microfilariae/mg skin, determined by four skin snips
  • Living in a village selected for the study.
  • Age ≥ 12 years.
  • All female participants of must commit to the use of a reliable method of for the duration of treatment and until 3 months after completion of dosing with product.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding.
  • Any concurrent condition that, in the opinion of the Investigator, would preclude evaluation of response to treatment or would pose undue risk to the participant's health.
  • Has received ivermectin, oral diethylcarbamazine (DEC) or doxycycline (for > 2 weeks) within 6 months of Baseline.
  • Has received treatment with an agent within the last 30 days (or 5 half-lives, whichever is longer) prior to Baseline.
  • Known or suspected allergy to ivermectin or moxidectin or their .
  • Self-reported planned or ongoing activities within the study period that would make it unlikely that a participant will be available for all planned treatment rounds and follow-up examinations.
  • Weight > 88 kg.
  • Infection with Loa loa.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
323 participants (actual)

Study arms

  • Experimental
    Annual Moxidectin

    Moxidectin 8mg per oral, administered annually for 24 months

    Drug: Moxidectin

  • Experimental
    Biannual Moxidectin

    Moxidectin 8mg per oral, administered biannually for 24 months

    Drug: Moxidectin

  • Active comparator
    Annual Ivermectin

    Ivermectin (approximately) 150 micrograms/kg per oral, administered annually for 24 months

    Drug: Ivermectin

  • Experimental
    Biannual Ivermectin

    Ivermectin (approximately) 150 micrograms/kg per oral, administered biannually for 24 months

    Drug: Ivermectin

Interventions

  • 2mg tablets, encapsulated for blinding

  • 3mg tablets, encapsulated for blinding

06

What researchers measure

Primary outcomes

  1. Proportion of moxidectin annual and biannual recipients with sustained microfilarial response at month 12

    Proportion of recipients with zero Onchocerca volvulus microfilariae/mg skin at all post-treatment timepoints to month 12

    Time frame: Up to 12 months

  2. Incidence and severity of adverse events

    Incidence and severity of adverse events, vital signs and liver function tests

    Time frame: Up to 36 months

Secondary outcomes

  1. Proportion of participants in all dose groups with sustained microfilariae response

    Proportion of participants with zero Onchocerca volvulus microfilariae/mg skin

    Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months

  2. Sustained ocular microfilariae response in all dose groups

    Proportion of participants with 0 live O. volvulus microfilariae in the anterior chambers of the eyes at all post-Baseline assessments in those with liver ocular microfilariae before the first treatment

    Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months

  3. Skin microfilarial density in all dose groups

    Mean, median and percentage reduction Onchocerca volvulus microfilariae/mg skin from baseline

    Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months

  4. Ocular microfilariae response in all dose groups

    Proportion of participants in all dose groups with 0 Onchocerca volvulus microfilariae/mg skin and 0 live microfilariae in the anterior chambers of the eyes each timepoint

    Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months

  5. Mean skin microfilariae density at each post-Screening assessment

    Mean and mean change from baseline of Onchocerca volvulus microfilariae/mg skin

    Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months

Other outcomes

  1. Signs and symptoms of onchocerciasis in all dose groups

    Proportion of participants with signs and symptoms of onchocerciasis with these signs and symptoms at baseline.

    Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months

  2. Viability and fertility of male and female macrofilariae in all dose groups

    Histopathological assessment of male and female macrofilariae excised from participants with palpable nodules

    Time frame: 36 months

07

Study locations

1 site
  • Centre de Recherche pour les Maladies Tropicales Negligees
    Rethy, Ituri, Democratic Republic of the Congo
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jul 2024, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2019
First posted
Mar 15, 2019
StartActual
May 3, 2021
Primary completionActual
Jul 31, 2024
CompletionEst.
Jan 1, 2026
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03876262
Lead sponsor
Medicines Development for Global Health
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
May 3, 2021
Primary completion
Jul 31, 2024
Completion
Jan 1, 2026 (estimated)
Last update
Dec 23, 2025

Study contacts

Tony Ukety, MD, DO, MPH
principal investigator · Centre de Recherche en Maladies Tropicales de l'Ituri

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Moxidectin · Ivermectin

Start the discussion